新城疫病毒pIRHN核酸疫苗构建和表达及对肿瘤细胞的影响

目的：研究NDV HN基因抗肿瘤作用及其可能机制。方法：以 pIRES1neo为表达载体构建了 NDV HN基因的pIRHN核酸疫苗，在体外转染HeLa细胞，用间接免疫荧光和Western blot检测pIRHN在真核细胞中表达状况，用荧光显微镜、DNA琼脂糖电泳及TUNEL染色等方法，检测HN基因导致细胞死亡的类型；用3，5-二羟基甲苯法测定HeLa细胞唾液酸含量的变化。结果：pIRHN 转染HeLa细胞后，能够在真核细胞中表达，能促进肿瘤细胞死亡，其死亡方式主要以诱导细胞凋亡为主，pIRHN使 HeLa细胞唾液酸含量减少。结论：用 NDV HN基因所构建的核酸疫苗能够在真核细胞中高效表达，表达的 HN蛋白主要位于胞膜，胞浆中亦有 HN蛋白表达；pIRHN具有抗肿瘤作用，可能通过其表达产物与肿瘤细胞唾液酸受体的相互作用，发挥其抗肿瘤作用。本实验为迸一步阐明NDV抗肿瘤作用机制提供了理论依据。     

从卵巢癌cDNA文库中筛选新的肿瘤标志物

采用SEREX法筛选了自行构建的中国人卵巢癌cDNA表达文库 ,得到 2 7个阳性克隆 ,其中 3个为全长cDNA。序列分析和同源性比对结果表明所获得的 2 7个克隆分属于分化抗原、细胞结构蛋白及功能未知三类。选择其中一个全长cDNAMY OVA 13(该基因编码的蛋白是MAD2 ) ,利用基因工程方法克隆、表达和纯化得到目的蛋白 ,采用点杂交方法检测了MY OVA 13目的蛋白与正常人和肿瘤患者中的血清学反应。MY OVA 13抗体只在肿瘤组中检测到 (5 / 74 ) ,在正常组中均为阴性 ;间接ELISA测定结果显示 ,MY OVA 13抗体的水平在肿瘤组中均高于正常组 ,其中肝癌和前列腺癌组与正常组相比 ,在统计学上有显著差异 ,P值分别 <0 0 1和 <0 0 5。我们的初步结果表明MY OVA 13及其抗体具有一定的肿瘤特异性 ,有可能作为肿瘤诊断的标志物     

HOXB7 siRNA表达载体在裸鼠体内对人恶性黑色素瘤细胞株的影响

目的 探讨转染同源盒第7基因(HOXB7)siRNA质粒表达载体对人恶性黑色素瘤细胞株A375在裸鼠体内生长的影响.方法 裸鼠皮下接种人恶性黑色素瘤A375细胞,对2周后形成的瘤块进行分组干预.随机分为生理盐水对照组、阴性质粒组、HOXB7质粒组,观察转染后各组裸鼠移植瘤的生长情况;免疫组化法比较瘤体内微血管密度(MVD).结果 HOXB7质粒组的裸鼠移植瘤块生长慢、体积明显小于生理盐水对照组[(0.134±0.039)cm3比(1.006±0.235)cm3,P＜0.05],而阴性质粒组瘤块体积大小与生理盐水对照组无统计学差异[(0.929±0.157)cm3比(1.006±0.235)cm3,P＞0.05].HOXB7质粒组裸鼠体内肿瘤MVD低于生理盐水对照组[(2.8±1.9)比(19.9±5.6),P＜0.05],阴性质粒组与生理盐水对照组无统计学差异[(18.1±5.5)比(19.9±5.6),P＞0.05].结论 针对HOXB7 siRNA质粒表达载体可有效抑制A375细胞裸鼠体内肿瘤生长和瘤内血管生成.     

强光干扰下的眩光评价研究

眩光是影响视觉的一个重要因素，而眩光后人眼的恢复时间则是进行眩光评价的重要标准。目前的眩光研究都是停留在针对普通照度的眩光源的研究背景下。通过对能产生高照度的眩光源照射后的人眼视觉恢复情况的实验研究，得到在强光干扰条件下的眩光影响因素关系。根据实验数据进行人眼恢复时间计算公式的修正，提出一种在强光干扰下对眩光的客观评价方法。通过实验，基本验证了该公式在高照度情况下的有效性和客观性。     

三维超声测胎儿股容积估计胎重的价值

目的通过对57例妊娠分别使用二维、三维超声测量相关参数估计胎重，并作统计学比较，从而评价三维超声对于估测胎儿体重、诊断胎儿发育迟缓及巨大胎的优势和价值。方法对2005年10月至2006年3月间在我院分娩的57例妊娠，研究组用三维超声测胎儿股容积估计胎重，对照组用二维超声同步测量相关参数估计胎重。结果对两组估重结果与胎儿实际出生体重作相关统计学分析，研究组相关系数为0．983，对照组为0．906（P〈0．05），前者与实际体重关系更密切。结论三维超声测量胎儿股容积估测胎儿体重，较传统二维超声具有更大优势，对于发现胎儿发育迟缓（FGR）及巨大胎意义重大，有利于指导临床冶疗、选择分娩方式。     

Hematopoietic Stem Cells Expansion in Rotating Wall Vessel

1 Introduction Clinical trials have demonstrated that ex vivo expanded hematopoietic stem cells (HSCs) and progenitors offer great promise in reconstituting in vivo hematopoiesis in patients who have undergone intensive chemotherapy.It is therefore necessary to develop a clinical-scale culture system to provide the expanded HSCs and progenitors.Static culture systems such as T-flasks and gas-permeable blood bags are the most widely used culture devices for expanding hematopoietic cells. But they reveal several inherent limitations: ineffective mixing, lack of control options for dissolved oxygen and pH and difficulty in continuous feeding, which restricts the usefulness of static systems. Several advanced bioreactors have been used in the field of HSCs expansion. But hematopoietic cells are extremely sensitive to shear, so cells in bioreactors such as stirred and perfusion culture systems may suffer physical damage. This problem will be improved by applying the rotating wall vessel (RWV) bioreactor in clinic because of its low shear and unique structure. In this research, cord blood (CB) HSCs were expanded by means of a cell-dilution feeding protocol in RWV.     

Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.

Relapsed acute myeloid leukemia (AML) in adults has a poor prognosis if treated with chemotherapy alone. Case series have previously supported the role of myeloablation and autologous transplantation as a potentially curative treatment. This study aimed to use the large numbers and extended follow-up data in the British Society of Blood and Marrow Transplantation (BSBMT) registry database to establish long-term outcomes and relate these to biological and procedural factors. The BSBMT registry database was used to retrospectively identify 152 adult patients (age, 16-69 years) with AML in second remission treated with autologous transplantation in 1982-2003. Cytogenetic data were available for 68% of the patients; of these, at diagnosis, 42% had good risk features, 57% had standard risk features, and 1% had poor risk features. Conditioning regimens varied; autologous rescue was provided with bone marrow (BM) (71%), peripheral blood stem cells (PBSCs) (18%), or both (11%), which were harvested during first complete remission (CR1) and/or second CR (CR2). Median follow-up was 84 months (range, 2-200 months). At 10 years, actuarial overall survival (OS) was 32%, progression-free survival (PFS) was 28%, and relapse rate (RR) was 57%. The 100-day nonrelapse mortality (NRM) was 7%, rising to 11% at 1 year and to 14% at 10 years. OS was significantly related to M3 subtype (5-year OS, 66%; P = .005), patient age at diagnosis (P = .005) and transplantation (P = .026), and length of CR1, with greatest significance if the patient was dichotomized at CR1 duration of < 8 months or > or = 8 months (P = .0001). There was no difference in OS between regimens containing total body irradiation (TBI) and chemotherapy alone (P = .7). In relation to the nature of autologous graft material, there was improved OS (P = .025) and PFS (P = .009) with the use of cells harvested entirely in CR1 compared with cells harvested in CR2 or in both CR1 and CR2. Engraftment times were significantly shortened with the use of PBSCs alone or in combination with BM compared with BM alone (P = .0001), but there was no significant long-term impact on OS, PFS, RR, or NRM. This study provides long-term follow-up data in one of the largest series of patients with standard-risk and good-risk AML in CR2 treated with autologous transplantation and supports earlier observations that long-term survival is achievable in about 1/3 of patients overall and in about 2/3 of patients with M3 with a relatively low NRM. Outcomes are better in patients with CR1 > or = 8 months by use of grafts obtained entirely in CR1 and use of PBSCs. TBI conditioning did not confer an advantage. Randomized studies against unrelated donor transplantation are warranted.     

绿色荧光蛋白、菲立磁体外双标记神经干细胞及其活性的研究

目的探索用绿色荧光蛋白(green fluorescent protein,GFP)重组逆转录病毒和菲立磁(超顺磁性氧化铁,,Superparamagnetic Iron Oxide,SPIO)体外双标记神经干细胞的可行性及其对细胞活力的影响。方法用病毒介导的GFP基因转导大鼠胚胎神经干细胞。用SPIO和Lipofectamine体外磁化标记经GFP标记的胚胎神经干细胞。用荧光显微镜观察双标记神经干细胞,并行普鲁士蓝染色,了解转染成功率。MTT(四甲基偶氮唑蓝)法检测标记神经干细胞的细胞增殖活力。结果双标记神经干细胞分化的细胞荧光显微镜下观察见发出绿色荧光,普鲁士蓝染色呈阳性。而未标记神经干细胞荧光显微镜下观察未见发出绿色荧光,普鲁士蓝染色呈阴性。MTT法检测发现GFP和SPIO双标记神经干细胞的增殖活力与未标记神经干细胞相比无改变。结论绿色荧光蛋白重组逆转录病毒和菲立磁可以有效地标记体外分离培养的大鼠胚胎神经干细胞。双标记神经干细胞的增殖、分化活力与未标记神经干细胞相比无改变。     

The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1α, and its interaction with indomethacin

Summary Pre-incubation of human platelets with nifedipine in vitro or treatment of normal volunteers with nifedipine, 30 mg daily for one week, did not alter ADP induced aggregation measured by whole blood aggregometry. 6-oxo-Prostaglandin F₁ remained undetectable in plasma following oral administration of nifedipine to normal volunteers. The hypotensive response to intravenous nifedipine administration was similar in spontaneously hypertensive rats pretreated with indomethacin or placebo. These results conflict with previous reports that nifedipine alters platelet aggregation and prostaglandin metabolism.     

柴胡加龙骨牡蛎汤治疗冠状动脉粥样硬化性心脏病合并焦虑抑郁研究进展

冠状动脉粥样硬化性心脏病（CHD）是全球常见的慢性病之一,焦虑和抑郁是其发生不良预后事件的潜在与关键危险因素。柴胡加龙骨牡蛎汤（CLMT）首见于《伤寒论》,为治疗少阳病兼心神逆乱证的经典名方,具备和解少阳、镇惊安神之功效。目前机制研究表明CLMT能通过调控相关信号通路、抑制相关炎症因子表达、改善氧化应激损伤、调节神经递质水平、抑制下丘脑-垂体-肾上腺轴亢进、促进骨髓间充质干细胞动员、抑制血小板活化等多途径对CHD合并焦虑抑郁发挥作用。临床研究表明CLMT对CHD合并焦虑抑郁导致的心绞痛、失眠等症状具有显著改善作用,可有效减轻患者负性情绪、改善中医证候积分、降低炎症因子水平等,且与西医常规治疗相比不良反应少,安全性较高。该文通过归纳整理近15年来中国知网（CNKI）、万方（Wanfang）、维普（VIP）、PubMed等数据库关于CLMT治疗CHD合并焦虑抑郁的文献,对其进行了机制及临床研究的综述,以期为CLMT指导CHD合并焦虑抑郁的进一步研究提供参考。